Wednesday, May 25, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

Current vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2 variants

by Medical Finance
in News
Omicron variant found to be much less sensitive to neutralizing antibodies than Delta
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2. These T cells can recognize SARS-CoV-2 Variants of Concern, including Delta and Omicron.

“The vast majority of T cell responses are still effective against Omicron,” says LJI Professor and study co-leader Alessandro Sette, Dr. Biol.Sci.

These cells won’t stop you from getting infected, but in many cases they are likely to keep you from getting very ill.”


Shane Crotty, Ph.D., LJI Professor

“And this is true in all the type of vaccines we studied-;and up to six months after vaccination,” says LJI Instructor Alba Grifoni, Ph.D., who co-led the work with Sette and Crotty.

These data come from adults who were fully vaccinated, but not yet boosted. The researchers are now investigating T cell responses in boosted individuals and people who have experienced “breakthrough” COVID-19 cases.

The new Cell study also shows that fully vaccinated people have fewer memory B cells and neutralizing antibodies against the Omicron variant. This finding is in line with initial reports of waning immunity from laboratories around the world.

Without enough neutralizing antibodies, Omicron is more likely to cause a breakthrough infection. Fewer memory B cells means the body will then be slower to churn out additional neutralizing antibodies to fight the virus.

“Most of the neutralizing antibodies, i.e., the antibodies that work well against SARS-CoV-2, bind to a region called the receptor binding domain, or RBD,” says LJI Instructor Camila Coelho, Ph.D., who served as co-first author of the study. “Our study revealed that the 15 mutations present in Omicron RBD can considerably reduce the binding capacity of memory B cells, compared to other SARS-CoV-2 variants such as Alpha, Beta and Delta.”

How T cells fight Omicron

The good news is that neutralizing antibodies and memory B cells are just two arms of the body’s adaptive immune response. In a person exposed to SARS-CoV-2, T cells do not prevent infection. Instead, T cells patrol the body and destroy cells that are already infected, which prevents a virus from multiplying and causing severe disease.

The LJI team believes the “second line of defense” from T cells helps explain why Omicron infections are less likely to lead to severe disease in fully vaccinated people. (The variant is also appears to infect different tissues)

To know whether the vaccine-induced T cells they detected in their study were actually effective against variants such as Delta and Omicron, the scientists took a close look at how the T cells responded to different viral “epitopes.”

Every virus is made up of proteins that form a certain shape or architecture. A viral epitope is a specific landmark on this architecture that T cells have been trained to recognize. The current COVID-19 vaccines were designed to teach the immune system to recognize specific epitopes on the initial “Alpha” variant of SARS-CoV-2. As the virus has mutated, its architecture has changed, and the concern is that immune cells will no longer recognize their targets.

The new study shows that while the architecture of Omicron is different enough to evade some neutralizing antibodies and memory B cells, memory T cells still do a good job of recognizing their targets, even on the highly mutated Omicron variant. Overall, at least 83 percent of the CD4+ (helper) T cell responses and 85 percent of the CD8+ T cell responses stayed the same, no matter the vaccine or the variant.

Crotty notes that the memory B cells that do bind Omicron are likely to also contribute to protection against severe disease. “Vaccinated people have memory CD4+ T cells, CD8+ T cells, and memory B cells to help fight the infection if the virus gets past the initial antibodies, and having multiple lines of defense is likely an important strength,” Crotty says.

Omicron is still a threat

The researchers emphasize that no one should count on T cell protection alone. The LJI study sheds light on immunity at the population level, but individual immune responses vary, and relying on one’s untested immune system to fight COVID is a roll of the dice.

“I’d urge people to still be cautious and keep wearing masks,” says Alison Tarke, a graduate student and member of the Sette Lab who served as co-first author with Coelho. “There is a chance you are one of the few people with a declining immune response.”

“This work also emphasizes the importance of getting a booster,” adds Sette.

The Sette and Crotty Labs have teamed up on COVID-19 research since early 2020. With the Sette Lab’s expertise in T cells and the Crotty Lab’s expertise in vaccine design and B cell responses, the collaboration has led to key insights into pre-existing SARS-CoV-2 immunity, vaccine responses, severe COVID cases and more.

Grifoni says the researchers are now looking at two pressing questions. First, they’d like to see what T cells, B cells and antibody responses look like after COVID-19 booster shots. Second, they are investigating what the immune response looks like after a breakthrough infection.

Source:

La Jolla Institute for Immunology

Journal reference:

Tarke, A., et al. (2022) SARS-CoV-2 vaccination induces immunological memory able to cross-recognize variants from Alpha to Omicron. Cell. doi.org/10.1016/j.cell.2022.01.015.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Climate change and the emergence of bat-borne viruses

Climate change and the emergence of bat-borne viruses

by Medical Finance
May 25, 2022
0

Many zoonotic diseases are sensitive to changes in climate as a result of shifting habitats that introduce contact between humans...

Horizontal gene transfer between viruses and hosts plays a major role in driving evolution

Study identifies a gene that plays an important role in embryo development

by Medical Finance
May 25, 2022
0

A new study co-led by a Cedars-Sinai investigator identified a gene that plays an important role in a biological pathway...

New approach using RNA therapeutic can fix protein problems in cystic fibrosis

UH experts in cloning and stem cell science take the first step toward unraveling cystic fibrosis

by Medical Finance
May 25, 2022
0

Two nationally recognized experts in cloning and stem cell science from the University of Houston are taking the first step...

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

Study reveals how processes in the human body could turn harmless immune cells into ruthless killers

by Medical Finance
May 25, 2022
0

Processes in the human body could turn groups of harmless immune cells into ruthless killers, capable of attacking other cells...

Improved viral RNA extraction from nasal and throat swab samples

Improved viral RNA extraction from nasal and throat swab samples

by Medical Finance
May 25, 2022
0

The Chromatrap® Homogeniser Spin Column from Porvair Sciences maximises the yield and quality of viral RNA extracted from nasal and...

New tool could help detect geographical hotspots for mental health problems caused by COVID

Blood groups play a key role in whether people develop severe COVID-19, study suggests

by Medical Finance
May 24, 2022
0

A new study has analyzed over 3000 proteins to identify which are causally linked to the development of severe COVID-19....

Next Post
Study: The changing impact of vaccines in the COVID-19 pandemic. Image Credit: Ramcreative / Shutterstock.com

Impact of new COVID vaccinations as novel variants emerge

Scientists discover antibody that inhibits a broad range of sarbecoviruses

Breakthrough infection could provide broad protection against current SARS-CoV-2 variants of concern

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • HEALTHCARE shutterstock 493063267 99928a5e003043f896998f01b025b9f6 620x480
    Congress shelves covid funding for now
  • Study: Inhibition of Protein N-Glycosylation Blocks SARS-CoV-2 Infection. Image Credit: Kateryna Kon / Shutterstock.com
    N-glycosylation blockers reduce SARS-CoV-2 infection
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply